LABFF Laboratorios Farmaceuticos Rovi, S.A. — dividend yield, history & ex-dividend dates
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin, and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikinet and Medicebrán provide treatment for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent populations. The firm also supplies a range of specialized hospital products for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventional procedures, Multihance and Prohance for MRI, and Sonovue for ultrasound examinations. Furthermore, Rovi provides advanced contrast injection systems, including EmpowerCTA+, EmpowerMR, and CT Exprès, along with their associated disposable components. Its portfolio extends to over-the-counter (OTC) pharmaceutical products. Moreover, Rovi offers contract development and manufacturing organization (CDMO) services to external businesses, producing pharmaceuticals in diverse forms such as prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi caters to a broad spectrum of healthcare stakeholders, encompassing wholesalers, physicians, nurses, pharmacists, and directly, patients. A notable partnership exists with Moderna, Inc., where Rovi is involved in the manufacturing of mRNA COVID-19 vaccine candidates. Established in 1946 and headquartered in Madrid, Spain,
Dividend Snapshot
Key Metrics
Current Yield
1.63%
The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.Annualized Dividend
$1.0963
The most recent payment scaled to a full year by how often it's paid. A $0.25 quarterly dividend annualizes to $1.00.Frequency
A Annual
How often the dividend is paid: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.Rank Score
41.3
Our 0-100 house score blending yield, payout safety, growth and momentum. Higher means a stronger profile on those factors in our model — a research score, not advice or a recommendation to buy.RSI (14)
0
Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.52-Week Range
$67.17 – $90.61
The lowest and highest price over the past year — shows where today's price sits in its recent range.Payout Ratio
34.06%
The share of GAAP earnings paid out as dividends. Lower leaves more cushion; above 100% means paying out more than the company earns. It shows n/a for BDCs, REITs and funds, which pay out of cash flow / net investment income rather than GAAP earnings, so this ratio doesn't apply.Years Paying
9
How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.Price / Book
5.94
Price-to-book ratio: share price divided by book value per share. A rough valuation gauge, most useful for asset-heavy sectors like REITs, banks and insurers.S.A.F.E. Dividend Read
Quote & Key Data
Dividend Growth
Why the Yield Moved (90 Days)
LABFF's dividend yield rose from 1.20% to 1.63% over the past ~90 days (+0.43 pp). Of that move, +0.01 pp came from changes in the dividend rate and +0.42 pp from the share price ($90.61 → $67.17). A yield that rises because the price fell is not an improvement in the payout itself.
Yield vs Its Own History
Across 332 daily observations over the past 16 months, LABFF's current yield is higher than approximately 92% of them. Our stored price history for LABFF covers the past 16 months; 3- and 5-year averages are not yet computable from it and are deliberately not shown.
Adjusted Price History
Dividend History
Dividend Payment History
Ex-dividend calendar →| Amount | Type | Declared | Ex-Date | Record | Pay |
|---|---|---|---|---|---|
| $1.0963 A | Regular | Feb 25, 2026 | Jul 14, 2026 | Jul 14, 2026 | Jul 15, 2026 |
| $1.0930 A | Regular | - | Jul 13, 2026 | Jul 14, 2026 | Jul 15, 2026 |
| $1.0864 A | Regular | Feb 25, 2025 | Jul 15, 2025 | Jul 15, 2025 | Jul 16, 2025 |
| $1.1934 A | Regular | Feb 27, 2024 | Jul 08, 2024 | Jul 09, 2024 | Jul 10, 2024 |
| $1.4126 A | Regular | - | Jul 03, 2023 | Jul 04, 2023 | Jul 05, 2023 |
| $0.9799 A | Regular | - | Jul 05, 2022 | Jul 06, 2022 | Jul 07, 2022 |
| $0.4342 S | Regular | - | Jul 06, 2021 | Jul 06, 2021 | Jul 07, 2021 |
| $0.4468 A | Regular | - | Jul 05, 2021 | Jul 06, 2021 | Jul 07, 2021 |
| $0.1684 A | Regular | - | Nov 17, 2020 | Nov 18, 2020 | Nov 19, 2020 |
| $0.0730 A | Regular | - | Jul 02, 2019 | Jul 03, 2019 | Jul 04, 2019 |
| $0.1139 A | Regular | - | Jul 03, 2018 | Jul 04, 2018 | Jul 05, 2018 |
| $0.1685 A | Regular | - | Jul 03, 2017 | Jul 04, 2017 | Jul 05, 2017 |
Peer Comparison
Selected Drug Manufacturers - Specialty & Generic dividend payers we cover, strongest DividendRank first — for context, not a recommendation.
| Ticker | Name | Yield | 5-Yr Growth | Streak | Rank |
|---|---|---|---|---|---|
| KSPHF | Kissei Pharmaceutical Co., Ltd. | 3.27% | 21.3% | 5 yrs | 78 |
| TSMRF | Tsumura & Co. | 4.41% | 20.8% | 3 yrs | 78 |
| NPNKF | Nippon Shinyaku Co., Ltd. | 3.42% | -0.2% | 0 yrs | 76 |
| SWGHF | Sawai Group Holdings Co., Ltd. | 3.15% | -1.8% | 0 yrs | 67 |
Related Guides & Lists
LABFF dividend — frequently asked questions
Does Laboratorios Farmaceuticos Rovi, S.A. pay a dividend?
Yes. Laboratorios Farmaceuticos Rovi, S.A. (LABFF) currently pays a dividend. The annualized dividend is about $1.10 per share, a yield of approximately 1.63%.
What is Laboratorios Farmaceuticos Rovi, S.A.'s dividend yield?
Laboratorios Farmaceuticos Rovi, S.A.'s dividend yield is approximately 1.63%, based on the most recent regular payment annualized against the current share price. Yields move as the share price changes.
How often does Laboratorios Farmaceuticos Rovi, S.A. pay dividends?
Laboratorios Farmaceuticos Rovi, S.A. pays dividends annually — 1 time per year.
How long has Laboratorios Farmaceuticos Rovi, S.A. paid dividends?
Laboratorios Farmaceuticos Rovi, S.A. has 9 years of dividend payments on record.
Data updated Sep 13, 2026. This research page is generated from Dividendly's structured market and dividend dataset using the approach described on our methodology and data sources pages. Data is automatically validated using defined rules and may also be periodically reviewed. Research only, not investment advice. Spotted a data error? Report it.